68Ga PET/CT在甲状腺髓样癌中检测骨转移优于其他影像学检查
一项前瞻性研究纳入30例甲状腺髓样癌患者(生化疾病组16例,转移性疾病组14例),比较68Ga PET/CT与常规影像学检查。结果显示68Ga PET/CT在检测骨转移方面敏感性为100%,优于骨扫描的44%,但在颈部淋巴结、肺转移和肝转移的敏感性较低。
要点
- 68Ga PET/CT检测骨转移敏感性100%,骨扫描为44%。
- 转移性疾病组中,68Ga PET/CT对颈部淋巴结、肺转移和肝转移敏感性分别为56%、57%和9%。
- 68Ga PET/CT不能作为甲状腺髓样癌单一全身成像程序。
核心结论
- 68Ga PET/CT不能提供甲状腺髓样癌患者最佳的单一全身成像程序。
- 68Ga PET/CT在检测骨病变方面高度敏感,可替代骨扫描和MRI。
研究设计与样本
- 前瞻性研究纳入30例甲状腺髓样癌患者,分为生化疾病组(n=16)和转移性疾病组(n=14)。
- 患者接受68Ga PET/CT、骨扫描、颈部CT和超声、胸部CT、腹部CT/MRI及脊柱MRI检查。
- 采用病理或细胞学分析或标准影像学明确识别计算敏感性和特异性,并比较生长抑素受体(SSTR)免疫组化与68Ga PET/CT结果。
主要发现
- 在两组中,除骨扫描外,68Ga PET/CT均劣于目前使用的影像学检查。
- 转移性疾病组中,68Ga PET/CT检测颈部淋巴结、肺转移和肝转移的敏感性分别为56%、57%和9%。
- 转移性疾病组中,68Ga PET/CT检测骨转移敏感性为100%,优于骨扫描的44%。
- 44%的肿瘤中观察到SSTR表达,但与68Ga-DOTATATE摄取无关。
临床怎么用
- 68Ga PET/CT由于在颈部淋巴结、肺和肝转移检测中敏感性较低,不推荐作为甲状腺髓样癌的单一全身成像程序。
- 68Ga PET/CT在检测骨病变方面高度敏感,可考虑替代骨扫描和MRI用于骨转移评估。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Persistent disease after surgery is common in medullary thyroid cancer (MTC), requiring lifelong radiological surveillance. Staging workup includes imaging of neck, chest, abdomen, and bones. A study integrating all sites would be ideal. Despite the established use of gallium-68 (68Ga) positron emission tomography (PET)/CT with somatostatin analogues in most neuroendocrine tumors, its efficacy is controversial in MTC. OBJECTIVE: Evaluate the efficacy of 68Ga PET/CT in detecting MTC lesions and evaluate tumor expression of somatostatin receptors (SSTRs) associated with 68Ga PET/CT findings. METHODS: Prospective study evaluating 30 patients with MTC [group 1 (n = 16), biochemical disease; group 2 (n = 14), metastatic disease]. Patients underwent 68Ga PET/CT, bone scan, CT and ultrasound of the neck, CT of the chest, CT/MRI of the abdomen, and MRI of the spine. 68Ga PET/CT findings were analyzed by disease site as positive or negative and as concordant or discordant with conventional studies. Sensitivity and specificity were calculated using pathological or cytological analysis or unequivocal identification by standard imaging studies. Immunohistochemical analysis of SSTRs was compared with 68Ga PET/CT findings. RESULTS: In both groups, 68Ga PET/CT was inferior to currently used imaging studies except for bone scan. In group 2, 68Ga PET/CT sensitivities were 56%, 57%, and 9% for detecting neck lymph nodes, lung metastases, and liver metastases, respectively, and 100% for bone metastases, superior to the bone scan (44%). Expression of SSTRs, observed in 44% of tumors, was not associated with 68Ga-DOTATATE uptake. CONCLUSIONS: 68Ga PET/CT does not provide optimal whole-body imaging as a single procedure in patients with MTC. However, it is highly sensitive in detecting bone lesions and could be a substitute for a bone scan and MRI.
引用
- Castroneves LA, Coura Filho G, de Freitas RMC, et al. Comparison of 68Ga PET/CT to Other Imaging Studies in Medullary Thyroid Cancer: Superiority in Detecting Bone Metastases. J Clin Endocrinol Metab. 2018. PMID: 29846642. doi:10.1210/jc.2018-00193
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。